CU23237A1 - PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS - Google Patents

PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS

Info

Publication number
CU23237A1
CU23237A1 CU20030285A CU20030285A CU23237A1 CU 23237 A1 CU23237 A1 CU 23237A1 CU 20030285 A CU20030285 A CU 20030285A CU 20030285 A CU20030285 A CU 20030285A CU 23237 A1 CU23237 A1 CU 23237A1
Authority
CU
Cuba
Prior art keywords
formulations
inducing
nmb1125
protein
antigen
Prior art date
Application number
CU20030285A
Other languages
English (en)
Inventor
Menendez Evelin Caballero
Diaz Darien Garcia
Garcia Gretel Sardinas
Negrin Yasser Perera
Blanco Sonia Gonzalez
Nunez Lazaro Hiram Betancourt
Perez Olivia Niebla
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Serra Lila Rosa Castellanos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030285A priority Critical patent/CU23237A1/es
Priority to ARP040104481A priority patent/AR047263A1/es
Priority to EP04802607A priority patent/EP1693378B9/en
Priority to DE602004023419T priority patent/DE602004023419D1/de
Priority to BRPI0417309-0A priority patent/BRPI0417309A/pt
Priority to US10/580,508 priority patent/US7691971B2/en
Priority to RU2006123434/13A priority patent/RU2336900C2/ru
Priority to KR1020067010712A priority patent/KR20060123759A/ko
Priority to CA002547317A priority patent/CA2547317A1/en
Priority to AU2004294376A priority patent/AU2004294376A1/en
Priority to PL04802607T priority patent/PL1693378T3/pl
Priority to AT04802607T priority patent/ATE444305T1/de
Priority to PCT/CU2004/000015 priority patent/WO2005054281A2/es
Priority to CNA2004800358779A priority patent/CN1890260A/zh
Priority to ES04802607T priority patent/ES2334138T3/es
Priority to NZ547520A priority patent/NZ547520A/xx
Priority to ZA200604556A priority patent/ZA200604556B/xx
Priority to NO20063020A priority patent/NO20063020L/no
Publication of CU23237A1 publication Critical patent/CU23237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapÉutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo tÉcnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patogenos. Para lograr este objetivo se aislo e identifico la proteína NMB1125 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clono y expreso el gen codificante para la proteína NMB1125, la cual se purifico evaluAndose luego se inmunogenicidad en biomodelos animales. El secuenciamiento de genes homologos evidencio, por su elevado grado de conservacion, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes de esta invencion son aplicables en la industria farmacÉutica como formulaciones vacUnales para uso humano.
CU20030285A 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS CU23237A1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
ARP040104481A AR047263A1 (es) 2003-12-03 2004-12-01 Proteina nmb1125 y su uso en formulaciones farmaceuticas
EP04802607A EP1693378B9 (en) 2003-12-03 2004-12-02 Protein nmb1125 and use thereof in pharmaceutical formulations
DE602004023419T DE602004023419D1 (de) 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen
BRPI0417309-0A BRPI0417309A (pt) 2003-12-03 2004-12-02 proteìna nmb1125 e seu uso em formulações farmacêuticas
US10/580,508 US7691971B2 (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
RU2006123434/13A RU2336900C2 (ru) 2003-12-03 2004-12-02 Белок nmb1125 и его применение в фармацевтических композициях
KR1020067010712A KR20060123759A (ko) 2003-12-03 2004-12-02 단백질 ｎｍｂ1125 및 약학적 제제에서의 이들의 용도
CA002547317A CA2547317A1 (en) 2003-12-03 2004-12-02 Protein nmb1125 and use thereof in pharmaceutical formulations
AU2004294376A AU2004294376A1 (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
PL04802607T PL1693378T3 (pl) 2003-12-03 2004-12-02 Białko NMB1125 i jego zastosowanie w kompozycjach farmaceutycznych
AT04802607T ATE444305T1 (de) 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen
PCT/CU2004/000015 WO2005054281A2 (es) 2003-12-03 2004-12-02 Proteína nmb1125 y su uso en formulaciones farmaceuticas
CNA2004800358779A CN1890260A (zh) 2003-12-03 2004-12-02 蛋白质nmb1125及其在药物制剂中的用途
ES04802607T ES2334138T3 (es) 2003-12-03 2004-12-02 Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas.
NZ547520A NZ547520A (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
ZA200604556A ZA200604556B (en) 2003-12-03 2006-06-02 Protein NMB 1125 and use thereof in pharmaceutical formulations
NO20063020A NO20063020L (no) 2003-12-03 2006-06-28 Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS

Publications (1)

Publication Number Publication Date
CU23237A1 true CU23237A1 (es) 2007-09-26

Family

ID=40091628

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS

Country Status (18)

Country Link
US (1) US7691971B2 (es)
EP (1) EP1693378B9 (es)
KR (1) KR20060123759A (es)
CN (1) CN1890260A (es)
AR (1) AR047263A1 (es)
AT (1) ATE444305T1 (es)
AU (1) AU2004294376A1 (es)
BR (1) BRPI0417309A (es)
CA (1) CA2547317A1 (es)
CU (1) CU23237A1 (es)
DE (1) DE602004023419D1 (es)
ES (1) ES2334138T3 (es)
NO (1) NO20063020L (es)
NZ (1) NZ547520A (es)
PL (1) PL1693378T3 (es)
RU (1) RU2336900C2 (es)
WO (1) WO2005054281A2 (es)
ZA (1) ZA200604556B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP2261343A3 (en) * 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CN1359426A (zh) * 1999-04-30 2002-07-17 希龙公司 奈瑟球菌基因组序列及其用法

Also Published As

Publication number Publication date
ES2334138T3 (es) 2010-03-05
WO2005054281A3 (es) 2005-08-04
EP1693378B9 (en) 2010-05-19
ATE444305T1 (de) 2009-10-15
CN1890260A (zh) 2007-01-03
KR20060123759A (ko) 2006-12-04
WO2005054281A2 (es) 2005-06-16
AU2004294376A1 (en) 2005-06-16
EP1693378A2 (en) 2006-08-23
AR047263A1 (es) 2006-01-11
BRPI0417309A (pt) 2007-09-11
NO20063020L (no) 2006-09-01
RU2006123434A (ru) 2008-01-10
DE602004023419D1 (de) 2009-11-12
CA2547317A1 (en) 2005-06-16
US7691971B2 (en) 2010-04-06
US20070218000A1 (en) 2007-09-20
EP1693378B1 (en) 2009-09-30
RU2336900C2 (ru) 2008-10-27
ZA200604556B (en) 2007-03-28
PL1693378T3 (pl) 2010-03-31
NZ547520A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
CY1123176T1 (el) Antimikpobiako πεπτιδιο και συνθεσεις αυτου
CY1117757T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
NO20044940L (no) Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet
CY1118555T1 (el) Γονιδιακη θεραπεια για την αμυοτροφικη πλευρικη σκληρυνση και αλλες διαταραχες της σπονδυλικης στηλης
CY1119091T1 (el) Πυριδυλοξυϊνδολες ως αναστολεις toy vegf-r2 και η χρηση τους στην θεραπεια νοσηματων
CY1108875T1 (el) Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα
WO2007022425A3 (en) Influenza recombinant subunit vaccine
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
CY1117872T1 (el) Ολιγοπεπτιδικες ενωσεις και χρησεις εξ' aυτων
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
CO6460752A2 (es) Respuesta inmunitaria reforzada en especies aviares
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
ATE457997T1 (de) Impfstoff gegen burkholderia-infektionen
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
CU23237A1 (es) PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
TW200505475A (en) Avian E. coli vaccine for protection against colibacillosis
CU23435A1 (es) Proteína nmb2134 y su uso en formulaciones farmacéuticas
CU23419A1 (es) Proteína nmb0088 y su uso en formulaciones farmacéuticas
NO20045587L (no) Liposom vaksineformulering for finne-fisk
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes